Abiraterone and MVD3100 take androgen deprivation to a new level.
Charlie
C
Schmidt
D000726:Androgen Antagonists / Q000494:pharmacology*; D000736:Androstenes; D000737:Androstenols / Q000494:pharmacology*; D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology*; D014408:Biomarkers, Tumor / Q000097:blood; D002318:Cardiovascular Diseases / Q000139:chemically induced; D017326:Clinical Trials, Phase III as Topic; D003920:Diabetes Mellitus / Q000139:chemically induced; D013196:Dihydrotestosterone / Q000037:antagonists & inhibitors; D017277:Drug Approval; D007987:Gonadotropin-Releasing Hormone / Q000009:adverse effects / Q000819:agonists; D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D016032:Randomized Controlled Trials as Topic; D013739:Testosterone / Q000037:antagonists & inhibitors*; D013997:Time Factors; D014481:United States; D014486:United States Food and Drug Administration
D000726:Androgen Antagonists; D000736:Androstenes; D000737:Androstenols; D018931:Antineoplastic Agents, Hormonal; D014408:Biomarkers, Tumor; D013196:Dihydrotestosterone; D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone; D017430:Prostate-Specific Antigen; C089740:abiraterone